OTCMKTS:MCUJFMedicure Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medicure Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.79 -0.05 (-5.95 %) (As of 08/6/2020 09:30 AM ET) Add Compare Share Today's Range$0.79Now: $0.79▼$0.8150-Day Range$0.69MA: $0.80▼$0.8552-Week Range$0.69Now: $0.79▼$4.00Volume4,700 shsAverage Volume860 shsMarket Capitalization$8.42 millionP/E RatioN/ADividend YieldN/ABeta0.26 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Medicure Inc., a cardiovascular pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, and Barbados. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non ST elevated acute coronary syndrome. The company's products also comprise PREXXARTAN, an oral solution used for the treatment of hypertension. In addition, it is developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications; and products for the treatment of acute cardiology. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Medicure. Previous Next 2.6 Community Rank Outperform VotesMedicure has received 149 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedicure has received 138 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedicure has received 51.92% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medicure and other stocks. Vote “Outperform” if you believe MCUJF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MCUJF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedicure does not currently pay a dividend.Dividend GrowthMedicure does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.90% of the stock of Medicure is held by insiders. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicure is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicure is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedicure has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MCUJF Previous Symbol CUSIPN/A CIKN/A Webwww.medicure.com Phone204-487-7412Debt Debt-to-Equity Ratio0.03 Current Ratio2.57 Quick Ratio1.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.20 million Price / Sales0.55 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book0.42Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-14,910,000.00 Net Margins-126.65% Return on Equity-33.24% Return on Assets-25.00%Miscellaneous EmployeesN/A Outstanding Shares10,660,000Market Cap$8.42 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable $0.79 -0.05 (-5.95 %) (As of 08/6/2020 09:30 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MCUJF News and Ratings via Email Sign-up to receive the latest news and ratings for MCUJF and its competitors with MarketBeat's FREE daily newsletter. Medicure (OTCMKTS:MCUJF) Frequently Asked Questions How has Medicure's stock been impacted by COVID-19 (Coronavirus)? Medicure's stock was trading at $1.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MCUJF stock has decreased by 38.8% and is now trading at $0.79. View which stocks have been most impacted by Coronavirus. When is Medicure's next earnings date? Medicure is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Medicure. How were Medicure's earnings last quarter? Medicure Inc. (OTCMKTS:MCUJF) issued its earnings results on Tuesday, May, 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The company had revenue of $2.24 million for the quarter. Medicure had a negative return on equity of 33.24% and a negative net margin of 126.65%. View Medicure's earnings history. Has Medicure been receiving favorable news coverage? Headlines about MCUJF stock have been trending negative on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medicure earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Medicure. Who are some of Medicure's key competitors? Some companies that are related to Medicure include SONNET BioTherapeutics (SONN), Sunesis Pharmaceuticals (SNSS), Pulmatrix (PULM), Akorn (AKRXQ), Newron Pharmaceuticals (NWPHF), Dare Bioscience (DARE), CNS Pharmaceuticals (CNSP), Akari Therapeutics (AKTX), Cyclerion Therapeutics (FBRX), Intec Pharma (NTEC), Provectus Biopharmaceuticals (PVCT), AzurRx BioPharma (AZRX), Kazia Therapeutics (KZIA), Alimera Sciences (ALIM) and PLx Pharma (PLXP). View all competitors. Who are Medicure's key executives? Medicure's management team includes the following people: Dr. Albert David Friesen, Founder, Chairman, CEO & Pres (Age 72)Mr. James F. Kinley, CFO & Sec. (Age 41) What is Medicure's stock symbol? Medicure trades on the OTCMKTS under the ticker symbol "MCUJF." How do I buy shares of Medicure? Shares of MCUJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Medicure's stock price today? One share of MCUJF stock can currently be purchased for approximately $0.79. How big of a company is Medicure? Medicure has a market capitalization of $8.42 million and generates $15.20 million in revenue each year. What is Medicure's official website? The official website for Medicure is www.medicure.com. How can I contact Medicure? Medicure's mailing address is 2 - 1250 WAVERLEY STREET, WINNIPEG A2, R3T 6C6. The company can be reached via phone at 204-487-7412 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
